Global Condyloma Acuminatum Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Condyloma Acuminatum Drugs Market Insights, Forecast to 2034
Condyloma acuminatum (also known as genital warts, acuminata, papilloma acuminatum) is a sexually transmitted infection caused by the human papillomavirus (HPV) that primarily affects the genital area and surrounding skin. Drug treatments for genital warts include the following types
Acid medicationsYour doctor may recommend some acid medications, such as citric acid, trichloroacetic acid, or salicylic acid, to help remove the wart. These medications cause the wart to gradually dry out, die off and fall off.
Immunomodulatory drugsSome drugs boost the activity of the local immune system to help the body fight viruses. These drugs include Imiquimod, which, when applied topically, prompts immune cells to release interferon, which inhibits viral growth.
Global Condyloma Acuminatum Drugs market is expected to reach to US$ 1871 million in 2024, with a positive growth of %, compared with US$ 1787 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Condyloma Acuminatum Drugs industry is evaluated to reach US$ 2464.6 million in 2029. The CAGR will be 4.7% during 2024 to 2029.
Factors such as rising prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections along with growing male population are expected to further drive the overall growth of the genital warts treatment market over the forecast period.
In addition, the effectiveness of topical administration of lamiquimod can be enhanced by concomitant use of IL-10 inhibitors, attracting more T cells and destroying HPV-infected keratinocytes of genital warts, thereby causing a stronger effect than vaccination. response to treatment.
Report Covers
This report presents an overview of global Condyloma Acuminatum Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Condyloma Acuminatum Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Bausch Health Companies Inc
Merck & Co., Inc
Taro Pharmaceutical Industries Ltd
CryoIQ
GSK Plc
BioNTech SE
Serum Institute of India Pvt。Ltd
Fotona
Orgenesis Inc
Perrigo Company plc
PerkinElmer Inc
Bio-Rad Laboratories, Inc.
Abbvie Inc
Phio Pharmaceuticals Corp
Teva Pharmaceutical Industries Ltd
Emblation Ltd
Segment by Type
Oral Medicine
External Drugs
Hospital
Specialist Clinic
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Condyloma Acuminatum Drugs plant distribution, commercial date of Condyloma Acuminatum Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Condyloma Acuminatum Drugs introduction, etc. Condyloma Acuminatum Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Condyloma Acuminatum Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Acid medicationsYour doctor may recommend some acid medications, such as citric acid, trichloroacetic acid, or salicylic acid, to help remove the wart. These medications cause the wart to gradually dry out, die off and fall off.
Immunomodulatory drugsSome drugs boost the activity of the local immune system to help the body fight viruses. These drugs include Imiquimod, which, when applied topically, prompts immune cells to release interferon, which inhibits viral growth.
Global Condyloma Acuminatum Drugs market is expected to reach to US$ 1871 million in 2024, with a positive growth of %, compared with US$ 1787 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Condyloma Acuminatum Drugs industry is evaluated to reach US$ 2464.6 million in 2029. The CAGR will be 4.7% during 2024 to 2029.
Factors such as rising prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections along with growing male population are expected to further drive the overall growth of the genital warts treatment market over the forecast period.
In addition, the effectiveness of topical administration of lamiquimod can be enhanced by concomitant use of IL-10 inhibitors, attracting more T cells and destroying HPV-infected keratinocytes of genital warts, thereby causing a stronger effect than vaccination. response to treatment.
Report Covers
This report presents an overview of global Condyloma Acuminatum Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Condyloma Acuminatum Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bausch Health Companies Inc
Merck & Co., Inc
Taro Pharmaceutical Industries Ltd
CryoIQ
GSK Plc
BioNTech SE
Serum Institute of India Pvt。Ltd
Fotona
Orgenesis Inc
Perrigo Company plc
PerkinElmer Inc
Bio-Rad Laboratories, Inc.
Abbvie Inc
Phio Pharmaceuticals Corp
Teva Pharmaceutical Industries Ltd
Emblation Ltd
Segment by Type
Oral Medicine
External Drugs
Segment by Application
Hospital
Specialist Clinic
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Condyloma Acuminatum Drugs plant distribution, commercial date of Condyloma Acuminatum Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Condyloma Acuminatum Drugs introduction, etc. Condyloma Acuminatum Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Condyloma Acuminatum Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices